InflaRx (IFRX) Payables (2016 - 2026)
InflaRx (IFRX) posted Payables of $5.7 million for Q1 2026, down 9.75% sequentially from $6.3 million in Q4 2025, and down 35.54% YoY from $8.8 million in Q1 2025.
InflaRx (IFRX) Payables (2016 - 2026) Analysis & Trends
InflaRx has reported Payables for 11 years, with the latest figure at $5.7 million in Q1 2026.
- Quarterly Payables fell 35.54% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (down 35.54% YoY) and the FY2025 annual result came in at $6.1 million, down 50.53% from the prior year.
- Payables declined to $5.7 million in Q1 2026 per IFRX's latest filing, from $6.3 million in the prior quarter.
- Over five years, Payables peaked at $12.9 million in Q4 2023 and troughed at $5.0 million in Q1 2023.
- A 5-year average of $8.6 million and a median of $8.4 million in 2022 frame the typical range for Payables.
- The widest YoY moves for Payables: up 153.19% in 2023, down 53.54% in 2023.
- Over 5 years, Payables stood at $5.1 million in 2022, then jumped by 153.19% to $12.9 million in 2023, then declined by 5.49% to $12.2 million in 2024, then tumbled by 48.38% to $6.3 million in 2025, then slipped by 9.75% to $5.7 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $5.7 million, $6.3 million, and $10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.67 Mn |
| Dec 31, 2025 | 6.29 Mn |
| Sep 30, 2025 | 10.79 Mn |
| Jun 30, 2025 | 11.02 Mn |
| Mar 31, 2025 | 8.80 Mn |
| Dec 31, 2024 | 12.18 Mn |
| Sep 30, 2024 | 12.87 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 8.26 Mn |
| Dec 31, 2023 | 12.88 Mn |
| Sep 30, 2023 | 6.53 Mn |
| Jun 30, 2023 | 5.66 Mn |
| Mar 31, 2023 | 4.95 Mn |
| Dec 31, 2022 | 5.09 Mn |
| Sep 30, 2022 | 7.50 Mn |
| Jun 30, 2022 | 8.44 Mn |
| Mar 31, 2022 | 10.67 Mn |
| Dec 31, 2021 | 9.81 Mn |
| Sep 30, 2021 | 13.58 Mn |
| Jun 30, 2021 | 10.76 Mn |